Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
A phase 2 trial of Tenalisib in triple-negative breast cancer, run by Rhizen Pharmaceuticals SA, now recruiting.
Overview
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) is a phase 2 interventional study registered as NCT06189209 by Rhizen Pharmaceuticals SA, with 40 participants planned, started 2024-03-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: Tenalisib.
Similar pages
not linked directly; found by shared links- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPersonalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialNuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialDual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.